Literature DB >> 25686144

Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.

M R Farhat1, C D Mitnick2, M F Franke3, D Kaur4, A Sloutsky4, M Murray5, K R Jacobson6.   

Abstract

Fluoroquinolone (FQ) drug susceptibility testing (DST) is an important step in the design of effective treatment regimens for multidrug-resistant tuberculosis. Here we compare ciprofloxacin, ofloxacin and moxifloxacin (MFX) resistance results from 226 multidrug-resistant samples. The low level of concordance observed suggests that DST should be performed for the specific FQ planned for clinical use. The results also support the new World Health Organization recommendation for testing MFX at a critical concentration of 2.0 μg/ml.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25686144      PMCID： PMC4486051          DOI： 10.5588/ijtld.14.0814

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  9 in total

Review 1.  The ins and outs of Mycobacterium tuberculosis drug susceptibility testing.

Authors:  E C Böttger
Journal:  Clin Microbiol Infect       Date:  2011-06-01       Impact factor: 8.067

Review 2.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

Review 3.  Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs.

Authors:  David J Horne; Lancelot M Pinto; Matthew Arentz; S-Y Grace Lin; Edward Desmond; Laura L Flores; Karen R Steingart; Jessica Minion
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

4.  In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.

Authors:  S Sulochana; F Rahman; C N Paramasivan
Journal:  J Chemother       Date:  2005-04       Impact factor: 1.714

5.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.

Authors:  Frederick A Sirgel; Robin M Warren; Elizabeth M Streicher; Thomas C Victor; Paul D van Helden; Erik C Böttger
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

6.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system.

Authors:  Yu Isaeva; A Bukatina; L Krylova; E Nosova; M Makarova; A Moroz
Journal:  J Antimicrob Chemother       Date:  2013-06-19       Impact factor: 5.790

8.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

9.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Authors:  Stephen H Gillespie; Angela M Crook; Timothy D McHugh; Carl M Mendel; Sarah K Meredith; Stephen R Murray; Frances Pappas; Patrick P J Phillips; Andrew J Nunn
Journal:  N Engl J Med       Date:  2014-09-07       Impact factor: 91.245
  9 in total
  9 in total

1.  Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.

Authors:  Hyun Lee; Soohyun Ahn; Na Young Hwang; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Chang-Ki Kim; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.

Authors:  Marva Seifert; Edmund Capparelli; Donald G Catanzaro; Timothy C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

3.  Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Authors:  Maha R Farhat; Karen R Jacobson; Molly F Franke; Devinder Kaur; Alex Sloutsky; Carole D Mitnick; Megan Murray
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

4.  Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.

Authors:  Jung-Yien Chien; Shun-Tien Chien; Wei-Yih Chiu; Chong-Jen Yu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Impact of Fluoroquinolone Use on Mortality Among a Cohort of Patients With Suspected Drug-Resistant Tuberculosis.

Authors:  Marva Seifert; Sophia B Georghiou; Richard S Garfein; Donald Catanzaro; Timothy C Rodwell
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

6.  Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Authors:  Courtney M Yuen; Ekaterina V Kurbatova; Thelma Tupasi; Janice Campos Caoili; Martie Van Der Walt; Charlotte Kvasnovsky; Martin Yagui; Jaime Bayona; Carmen Contreras; Vaira Leimane; Julia Ershova; Laura E Via; HeeJin Kim; Somsak Akksilp; Boris Y Kazennyy; Grigory V Volchenkov; Ruwen Jou; Kai Kliiman; Olga V Demikhova; Irina A Vasilyeva; Tracy Dalton; J Peter Cegielski
Journal:  PLoS Med       Date:  2015-12-29       Impact factor: 11.069

7.  Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.

Authors:  Michael L Chen; Akshith Doddi; Jimmy Royer; Luca Freschi; Marco Schito; Matthew Ezewudo; Isaac S Kohane; Andrew Beam; Maha Farhat
Journal:  EBioMedicine       Date:  2019-04-29       Impact factor: 8.143

8.  Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.

Authors:  Hui Xia; Yang Zheng; Dongxin Liu; Shengfen Wang; WenCong He; Bing Zhao; Yuanyuan Song; Xichao Ou; Yang Zhou; Susan van den Hof; Frank Cobelens; YanLin Zhao
Journal:  Microbiol Spectr       Date:  2021-12-01

9.  Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.

Authors:  Maha R Farhat; Karen R Jacobson; Molly F Franke; Devinder Kaur; Megan Murray; Carole D Mitnick
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.